Empagliflozin advancing on all fronts: Readying for the future with EMPEROR
In this final issue of our series, join us as we look into the upcoming results of the pivotal EMPEROR trials, which will investigate the use of empagliflozin in patients with either preserved or reduced ejection fraction heart failure, with or without type 2 diabetes. Understand why heart failure has such a high clinical burden, and the great unmet need in providing solutions for it.

New Molecule

2 New

New Formulation

1 New

New Brand

1 New

Color 1
Color 2